No Data
No Data
Novo Nordisk Gains Exclusive Rights to Lexicon's Non-incretin Obesity Drug Candidate
While Wall Street Panicked, These 3 Hidden Small-Caps Exploded Last Week — One Surging A Jaw-Dropping 60%
Trending Stocks Today | Portage Biotech Shoots up 98.51%
Top Midday Gainers
Express News | HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $4 Price Target
Lexicon Pharmaceuticals Analyst Ratings